Related Experiment Video
Updated: Jul 6, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Effect of antibody-targeted chemotherapy with pingyangmycin on prostate cancer cells in vitro]
Wei-zhen Chen1, Yong Zhang, Chang-sheng Liang
1Department of Nuclear Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
Objective:
To investigate the effect of antibody-targeted chemotherapy against human prostate cancer LNCaP cells in vitro.
Methods:
The monoclonal antibody 7E11C5.3 against human prostate cancer was conjugated to pingyangmycin (PYM), mediated by dextran T-40, and the immunoreactivity of 7E11C5.3 was determined by indirect enzyme-linked immunosorbent assay. The bacteriostatic activity of the conjugate was determined using TTC assay, and its cytotoxicity against LNCaP cells was determined by MTT assay.
Results:
The 7E11C5.3:PYM molar ratio was l:54 in the conjugate, and the immunoreactivity of 7E11C5.3 was decreased by approximately 10% to 20% after conjugation. The bacteriostatic activity of conjugated PYM was 25% of that of free PYM. The 50% inhibitory doses (IC50) of 7E11C5.3-PYM conjugate and free PYM against the in vitro cultured LNCaP cells were 9.41-/+1.98 microg/ml and 29.92-/+7.88 microg/ml, respectively.
Conclusion:
7E11C5.3-PYM conjugate displays stronger cytotoxicity against anti-prostate cancer effects than free PYM.
